Prosonix has raised £11.4m in Series B funding to move its pipeline of proprietary mono and multi-component combination respiratory therapies through phase II clinical trials. Ventech led the round with Gilde Healthcare Partners joining existing investors the Entrepreneurs Fund, Solon Ventures and Quest for Growth. David Hipkiss, Prosonix's CEO said "these new funds will allow us to attain key performance and clinical data for our pipeline of advanced fast-to-market respiratory programs that will deliver significant added value and benefits to patients and payors alike."
In-pharma Technologist
Thursday 30 June 2011
Prosonix secures funding
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment